Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05929300 | A Yoga Program for Patients Undergoing Prostate Cancer Surgery | N/A | withdrawn | Jul 3, 2023 | VA Office of Research and Development | Lack of recruitment | Enrollment / accrual |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | Phase 1 / Phase 2 | withdrawn | Mar 26, 2024 | Baptist Health South Florida | Funding for the study was withdrawn. | Funding |
| NCT00773773 | Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can… | N/A | terminated | Oct 16, 2008 | Memorial Sloan Kettering Cancer Center | Protocol closed to accrual early due to PI retirement. | Enrollment / accrual |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell… | Phase 2 | terminated | Jun 11, 2018 | Roberto Pili | Funder halted development of compound in this disease | Other (stated, no rule matched) |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of…(NIVIX) | Phase 1 / Phase 2 | terminated | Aug 23, 2018 | Michelle S Ludwig | A recent change in treatment landscape may make study futile | Other (stated, no rule matched) |
| NCT00321698 | Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for… | Phase 1 / Phase 2 | terminated | May 4, 2006 | OHSU Knight Cancer Institute | Funding withdrawal | Funding |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy… | Phase 2 | terminated | Jan 27, 2011 | Merck Sharp & Dohme LLC | Persistent low enrollment made study continuation no longer feasible | Enrollment / accrual |
| NCT03056638 | Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | Phase 3 | terminated | Feb 17, 2017 | Memorial Sloan Kettering Cancer Center | Due to low accrual | Enrollment / accrual |
| NCT04248153 | Optimal Timing of BR55 CEUS of the Ovaries | Phase 2 | terminated | Jan 30, 2020 | Bracco Diagnostics, Inc | Sponsor decision; expiration of available study agent due to long recruitment timeline. | Enrollment / accrual |
| NCT04849858 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic… | Phase 3 | terminated | Apr 19, 2021 | University of California, Irvine | Low recruitment | Enrollment / accrual |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who… | — | withdrawn | Oct 3, 2011 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 8, 2009 | NantCell, Inc. | Sponsor decision - subjects rolled over to protocol 20101116 | Sponsor / business decision |
| NCT04377087 | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent… | Phase 2 | terminated | May 6, 2020 | Sarah E Taylor | Slow enrollment | Enrollment / accrual |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | Phase 1 | withdrawn | Jan 22, 2024 | University of California, San Diego | closed early due to low (0) accrual | Enrollment / accrual |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | terminated | Feb 22, 2019 | Hinova Pharmaceuticals USA, Inc. | Terminated by Sponsor for various factors including prolonged duration and enrollment challenges | Enrollment / accrual |
| NCT01199250 | Biomarkers in Samples From Patients With Endometrial Cancer | — | withdrawn | Sep 10, 2010 | Gynecologic Oncology Group | Not a treatment/applicable clinical trial | Other (stated, no rule matched) |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT05415696 | Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in… | N/A | withdrawn | Jun 13, 2022 | Stanford University | Enrolling to this clinical trial was too difficult | Enrollment / accrual |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and… | Phase 1 | terminated | Feb 20, 2009 | Astex Pharmaceuticals, Inc. | The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in… | Safety / toxicity |
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in… | Phase 1 | terminated | Nov 16, 2020 | Swiss Cancer Institute | SAKK decided to premature terminate this trial as additional follow-up visits do not further… | Efficacy / futility |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline… | Phase 2 | withdrawn | Oct 10, 2022 | AdventHealth | PI Decision based on no enrollment | Enrollment / accrual |
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in… | Phase 1 / Phase 2 | terminated | Oct 27, 2017 | ModernaTX, Inc. | This study was halted prematurely because the efficacy endpoints were not met for either treatment… | Efficacy / futility |
| NCT04293406 | pCHIP: Prostate Cancer Health Impact Program | — | terminated | Mar 3, 2020 | Weill Medical College of Cornell University | Study has been stopped due to lack of follow up questionnaires being completed. | Other (stated, no rule matched) |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 29, 2020 | NextCure, Inc. | Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on… | Other (stated, no rule matched) |
| NCT03134027 | Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of…(Immune PDX) | — | terminated | Apr 28, 2017 | Duke University | Poor accrual | Enrollment / accrual |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Nov 12, 2019 | Barbara Ann Karmanos Cancer Institute | The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA… | Safety / toxicity |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and… | Phase 2 | terminated | Feb 20, 2018 | M.D. Anderson Cancer Center | Project delays | Other (stated, no rule matched) |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | Phase 2 | terminated | Dec 10, 2018 | Jodi Layton, MD | Early signs of progression and learned experience that the assumed time period between psa… | Other (stated, no rule matched) |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | Phase 1 | withdrawn | Feb 21, 2023 | Insel Gruppe AG, University Hospital Bern | IMP security Issues reported by Sponsor | Other (stated, no rule matched) |
| NCT00330564 | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have… | Phase 2 | terminated | May 29, 2006 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Sep 26, 2018 | Pfizer | The decision to stop enrollment was due to strategic considerations and not due to any specific… | Safety / toxicity |
| NCT03905889 | A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | Phase 1 | terminated | Apr 5, 2019 | Brown University | Funding withdrawn | Funding |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced… | Phase 2 | terminated | Oct 1, 2018 | Effector Therapeutics | Terminated early due to a lack of efficacy. | Efficacy / futility |
| NCT03367871 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | Phase 2 | terminated | Dec 11, 2017 | University of Miami | Investigator left institution | Investigator |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder…(ATLAS) | Phase 3 | terminated | Dec 30, 2020 | UroGen Pharma Ltd. | Alternate approach pursued | Other (stated, no rule matched) |
| NCT05643690 | Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay | — | suspended | Dec 9, 2022 | AnchorDx Medical Co. Ltd. US | Protocol amendment. | Other (stated, no rule matched) |
| NCT03632655 | A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy… | N/A | terminated | Aug 15, 2018 | Weill Medical College of Cornell University | The study was terminated due to procurement of new funding sources. | Funding |
| NCT02542202 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent… | N/A | terminated | Sep 4, 2015 | University of Chicago | due to slow enrollment | Enrollment / accrual |
| NCT01794936 | Pilot Study of VTI Doppler Probe Use to Identify Neurovascular Bundle During Prostate… | N/A | terminated | Feb 20, 2013 | Columbia University | PI left the institution | Investigator |
| NCT03458234 | RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate…(RAD1801) | N/A | terminated | Mar 8, 2018 | University of Alabama at Birmingham | No longer manufacturing radiotransponder beacons. No similar product available. The results are no… | Drug supply |
| NCT03562507 | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic…(ERICA) | Phase 2 | terminated | Jun 19, 2018 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT04004884 | Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)(LISA) | — | terminated | Jul 2, 2019 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Lack of recruitment | Enrollment / accrual |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Sep 19, 2024source: clinicaltrials